Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Purpose
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Conditions
- B Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
- Lymphoblastic Lymphoma
- Mixed Phenotype Acute Leukemia
- T Acute Lymphoblastic Leukemia
Eligibility
- Eligible Ages
- Between 15 Years and 40 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- >= 15 and < 40 years at time of diagnosis - Newly diagnosed B-ALL, T-ALL, lymphoblastic lymphoma (LLy), or mixed-phenotype acute leukemia/lymphoma (MPAL) - Note: Philadelphia chromosome (PH)+ and PH-like acute leukemia are eligible (use of tyrosine kinase inhibitors [TKI] or CRLF2- targeted concomitant medication must be documented, if used) - Conjugated bilirubin =< 1.5 x upper limit of normal (ULN) for age, regardless of baseline bilirubin (within 7 days prior to enrollment), and - Serum glutamate pyruvate transaminase (SGPT) (ALT) =< 225 U/L (=< 5x ULN) (within 7 days prior to enrollment), and - Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L and serum glutamic oxaloacetic transaminase (SGOT) (AST) to 50 U/L regardless of baseline - SGOT (AST) =< 250 U/L (=< 5x ULN) (within 7 days prior to enrollment) - Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L and SGOT (AST) to 50 U/L regardless of baseline - For patients receiving ursodiol prior to enrollment, laboratory values must meet above criteria off ursodiol for 7 days - PEDIATRIC PATIENTS (AGE 15-17 years): - A 24-hour urine creatinine clearance >= 30 mL/min/1.73 m^2 (within 7 days prior to enrollment) OR - A glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2. GFR must be performed using one of the following methods (within 7 days prior to enrollment): - 1. Estimated GFR (eGFR) >= 30 mL/min/1.73 m^2. - An online calculator is available through the National Kidney Foundation at https://www.kidney.org/professionals/kdoqi/gfr_calculatorped - 2. Measured GFR >= 30 mL/min/1.73 m^2 (any age). If measured GFR is used, it must be performed using direct measurement with a nuclear blood sampling method or small molecule clearance method (iothalamate or other molecule per institutional standard). - ADULT PATIENTS (AGE 18 YEARS OR OLDER): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection (within 7 days prior to enrollment). Estimated creatinine clearance is based on actual body weight - An online calculator is available through the National Kidney Foundation at https://www.kidney.org/professionals/kdoqi/gfr_calculatorcoc - Berlin-Frankfurt-Munich (BFM), Children's Oncology Group (COG), or C10403-based Induction regimen and must be inclusive of >= 1 dose of pegaspargase or calaspargase pegol, and - First dose of asparaginase must be planned within the first week of induction therapy, and - Dose of pegaspargase or calaspargase pegol must be >= 1,000 IU/ m^2 (dose-capping permitted per primary regimen) - Note: Co-enrollment on a therapeutic consortia trial is not required - All patients and/or their parents or legal guardians must sign a written informed consent - All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria
- Down syndrome - Known inherited or autoimmune liver disease impacting conjugated bilirubin (e.g., Alagille syndrome, primary sclerosing cholangitis, other) - Known biopsy (or imaging) proven severe liver fibrosis (Batts-Ludwig >= stage 3) - Unable to tolerate oral formulation of study drug at enrollment - Patients who received chemotherapy or treatment for a prior malignancy are not eligible - The following are permitted: steroid prophase, hydroxyurea, or other cytoreduction prior to initiation of Induction chemotherapy (must be documented) and chemotherapy for current diagnosis (i.e. initiation of Induction therapy within enrollment window). Chemotherapy prior to enrollment for treatment of a non-malignancy (e.g., steroid or methotrexate for autoimmune disease) is also permitted and must be documented - Female patients who are pregnant since fetal toxicities and teratogenic effects in humans are unknown for study drug. A pregnancy test is required for female patients of childbearing potential - Lactating females who plan to breastfeed their infants - Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Parallel with the option to cross over to Arm C to begin levocarnitine rescue
- Primary Purpose
- Supportive Care
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm A (levocarnitine, standard of care chemotherapy) |
Patients receive levocarnitine PO or IV as a bolus over 2 to 3 minutes or by infusion (over 10 to 30 minutes or per institutional standard) starting prior to standard of care induction chemotherapy with pegaspargase or calaspargase pegol and continued through the earlier of the last day of Induction phase (i.e., day prior to start of next phase) or Induction day 35. Patients may also undergo blood sample collection during screening and on study. |
|
|
Active Comparator Arm B (standard of care chemotherapy) |
Patients receive standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study. |
|
|
Experimental Arm C (rescue levocarnitine) |
Patients in Arms A and B who develop conjugated hyperbilirubinemia > 3 mg/dL during induction may receive levocarnitine rescue PO or IV as a bolus dose over 2 to 3 minutes or by infusion (over 10 to 30 minutes or per institutional standard) until resolution of conjugated hyperbilirubinemia =< 3 mg/dL (or start of consolidation or the next treatment phase, whichever occurs first). |
|
Recruiting Locations
Birmingham 4049979, Alabama 4829764 35233
Anchorage 5879400, Alaska 5879092 99508
Kingman 5301067, Arizona 5551752 86401
Phoenix 5308655, Arizona 5551752 85016
Site Public Contact
602-546-0920
Tucson 5318313, Arizona 5551752 85719
Little Rock 4119403, Arkansas 4099753 72202-3591
Site Public Contact
501-364-7373
Anaheim 5323810, California 5332921 92806
Arroyo Grande 5324802, California 5332921 93420
Bellflower 5327422, California 5332921 90706
Downey 5343858, California 5332921 90242
Site Public Contact
626-564-3455
Duarte 5344147, California 5332921 91010
Fontana 5349755, California 5332921 92335
Loma Linda 5367696, California 5332921 92354
Site Public Contact
909-558-4050
Long Beach 5367929, California 5332921 90806
Site Public Contact
562-933-5600
Los Angeles 5368361, California 5332921 90027
Site Public Contact
323-361-4110
Los Angeles 5368361, California 5332921 90027
Madera 5369568, California 5332921 93636
Oakland 5378538, California 5332921 94609
Palo Alto 5380748, California 5332921 94304
Palo Alto 5380748, California 5332921 94304
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
San Diego 5391811, California 5332921 92108
San Diego 5391811, California 5332921 92120
San Francisco 5391959, California 5332921 94158
Aurora 5412347, Colorado 5417618 80045
Denver 5419384, Colorado 5417618 80218
Wilmington 4145381, Delaware 4142224 19803
Washington D.C. 4140963, District of Columbia 4138106 20010
Fort Myers 4155995, Florida 4155751 33908
Gainesville 4156404, Florida 4155751 32610
Hollywood 4158928, Florida 4155751 33021
Jacksonville 4160021, Florida 4155751 32207
Miami 4164138, Florida 4155751 33155
Site Public Contact
888-624-2778
Miami 4164138, Florida 4155751 33176
Site Public Contact
786-596-2000
Orlando 4167147, Florida 4155751 32803
Orlando 4167147, Florida 4155751 32827
Pensacola 4168228, Florida 4155751 32504
St. Petersburg 4171563, Florida 4155751 33701
Tampa 4174757, Florida 4155751 33606
Tampa 4174757, Florida 4155751 33607
Atlanta 4180439, Georgia 4197000 30329
Savannah 4221552, Georgia 4197000 31404
Honolulu 5856195, Hawaii 5855797 96826
Site Public Contact
808-983-6090
Boise 5586437, Idaho 5596512 83712
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Twin Falls 5610810, Idaho 5596512 83301
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Chicago 4887398, Illinois 4896861 60637
Oak Lawn 4904365, Illinois 4896861 60453
Site Public Contact
847-723-7570
Park Ridge 4905367, Illinois 4896861 60068
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Indianapolis 4259418, Indiana 4921868 46202
Site Public Contact
800-248-1199
Indianapolis 4259418, Indiana 4921868 46260
Des Moines 4853828, Iowa 4862182 50309
Iowa City 4862034, Iowa 4862182 52242
Site Public Contact
800-237-1225
Kansas City 4273837, Kansas 4273857 66160
Westwood 4281639, Kansas 4273857 66205
Lexington 4297983, Kentucky 6254925 40536
Site Public Contact
859-257-3379
Louisville 4299276, Kentucky 6254925 40202
New Orleans 4335045, Louisiana 4331987 70118
Site Public Contact
504-894-5377
New Orleans 4335045, Louisiana 4331987 70121
Scarborough 4977882, Maine 4971068 04074
Baltimore 4347778, Maryland 4361885 21215
Site Public Contact
410-601-9083
Baltimore 4347778, Maryland 4361885 21287
Ann Arbor 4984247, Michigan 5001836 48109
Site Public Contact
800-865-1125
Ann Arbor 4984247, Michigan 5001836 48109
Battle Creek 4985153, Michigan 5001836 49017
Detroit 4990729, Michigan 5001836 48201
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49009
Site Public Contact
574-647-7370
Kalamazoo 4997787, Michigan 5001836 49048
Site Public Contact
574-647-7370
Muskegon 5003132, Michigan 5001836 49444
Niles 5003514, Michigan 5001836 49120
Site Public Contact
616-391-1230
Norton Shores 5004005, Michigan 5001836 49444
Reed City 5006946, Michigan 5001836 49677
Saint Joseph 5008327, Michigan 5001836 49085
Saint Joseph 5008327, Michigan 5001836 49085
Traverse City 5012495, Michigan 5001836 49684
Wyoming 5015618, Michigan 5001836 49519
Rochester 5043473, Minnesota 5037779 55905
Site Public Contact
855-776-0015
Jackson 4431410, Mississippi 4436296 39216
Site Public Contact
601-815-6700
Kansas City 4393217, Missouri 4398678 64108
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Omaha 5074472, Nebraska 5073708 68114
Site Public Contact
402-955-3949
Omaha 5074472, Nebraska 5073708 68198
Carson City 5501344, Nevada 5509151 89703
Henderson 5505411, Nevada 5509151 89052
Henderson 5505411, Nevada 5509151 89052
Henderson 5505411, Nevada 5509151 89052
Henderson 5505411, Nevada 5509151 89074
Henderson 5505411, Nevada 5509151 89074
Henderson 5505411, Nevada 5509151 89074
Henderson 5505411, Nevada 5509151 89074
Henderson 5505411, Nevada 5509151 89074
Las Vegas 5506956, Nevada 5509151 89074
Las Vegas 5506956, Nevada 5509151 89102
Las Vegas 5506956, Nevada 5509151 89102
Las Vegas 5506956, Nevada 5509151 89103
Las Vegas 5506956, Nevada 5509151 89106
Las Vegas 5506956, Nevada 5509151 89106
Las Vegas 5506956, Nevada 5509151 89109
Las Vegas 5506956, Nevada 5509151 89113
Las Vegas 5506956, Nevada 5509151 89113
Las Vegas 5506956, Nevada 5509151 89119
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89135
Las Vegas 5506956, Nevada 5509151 89144
Las Vegas 5506956, Nevada 5509151 89144
Las Vegas 5506956, Nevada 5509151 89144
Las Vegas 5506956, Nevada 5509151 89148
Las Vegas 5506956, Nevada 5509151 89148
Las Vegas 5506956, Nevada 5509151 89169
Pahrump 5509851, Nevada 5509151 89048
Reno 5511077, Nevada 5509151 89502
Reno 5511077, Nevada 5509151 89503
Reno 5511077, Nevada 5509151 89509
Hackensack 5098706, New Jersey 5101760 07601
Site Public Contact
551-996-2897
Neptune City 5101687, New Jersey 5101760 07753
Site Public Contact
732-776-4240
Newark 5101798, New Jersey 5101760 07112
Paterson 5102466, New Jersey 5101760 07503
Albuquerque 5454711, New Mexico 5481136 87106
Albuquerque 5454711, New Mexico 5481136 87106
Albany 5106834, New York 5128638 12208
Site Public Contact
518-262-5513
Mineola 5127134, New York 5128638 11501
New Hyde Park 5128514, New York 5128638 11040
Site Public Contact
718-470-3460
New York 5128581, New York 5128638 10065
Site Public Contact
212-746-1848
Stony Brook 5139865, New York 5128638 11794
Site Public Contact
800-862-2215
The Bronx 5110266, New York 5128638 10461
The Bronx 5110266, New York 5128638 10461
The Bronx 5110266, New York 5128638 10467
The Bronx 5110266, New York 5128638 10467
Valhalla 5142090, New York 5128638 10595
Site Public Contact
914-594-3794
Chapel Hill 4460162, North Carolina 4482348 27599
Charlotte 4460243, North Carolina 4482348 28203
Site Public Contact
800-804-9376
Winston-Salem 4499612, North Carolina 4482348 27157
Site Public Contact
336-713-6771
Fargo 5059163, North Dakota 5690763 58122
Akron 5145476, Ohio 5165418 44308
Site Public Contact
330-543-3193
Cincinnati 4508722, Ohio 5165418 45229
Cleveland 5150529, Ohio 5165418 44106
Site Public Contact
216-844-5437
Cleveland 5150529, Ohio 5165418 44195
Columbus 4509177, Ohio 5165418 43205
Dayton 4509884, Ohio 5165418 45404
Site Public Contact
800-228-4055
Toledo 5174035, Ohio 5165418 43606
Oklahoma City 4544349, Oklahoma 4544379 73104
Tulsa 4553433, Oklahoma 4544379 74136
Site Public Contact
918-494-2200
Portland 5746545, Oregon 5744337 97239
Danville 5186327, Pennsylvania 6254927 17822
Hershey 5193342, Pennsylvania 6254927 17033
Site Public Contact
717-531-6012
Philadelphia 4560349, Pennsylvania 6254927 19104
Pittsburgh 5206379, Pennsylvania 6254927 15224
Greenville 4580543, South Carolina 4597040 29601
Greenville 4580543, South Carolina 4597040 29605
Greenville 4580543, South Carolina 4597040 29605
Greenville 4580543, South Carolina 4597040 29607
Greenville 4580543, South Carolina 4597040 29615
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Knoxville 4634946, Tennessee 4662168 37916
Site Public Contact
865-541-8266
Nashville 4644585, Tennessee 4662168 37203
Site Public Contact
615-342-1919
Nashville 4644585, Tennessee 4662168 37232
Site Public Contact
800-811-8480
Austin 4671654, Texas 4736286 78723
Corpus Christi 4683416, Texas 4736286 78411
Dallas 4684888, Texas 4736286 75230
Site Public Contact
972-566-5588
Dallas 4684888, Texas 4736286 75390
El Paso 5520993, Texas 4736286 79905
Fort Worth 4691930, Texas 4736286 76104
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
Lubbock 5525577, Texas 4736286 79410
Lubbock 5525577, Texas 4736286 79415
Site Public Contact
806-775-8590
San Antonio 4726206, Texas 4736286 78207
San Antonio 4726206, Texas 4736286 78229
San Antonio 4726206, Texas 4736286 78229
Charlottesville 4752031, Virginia 6254928 22908
Falls Church 4758390, Virginia 6254928 22042
Norfolk 4776222, Virginia 6254928 23507
Richmond 4781708, Virginia 6254928 23298
Roanoke 4782167, Virginia 6254928 24014
Renton 5808189, Washington 5815135 98055
Seattle 5809844, Washington 5815135 98105
Site Public Contact
866-987-2000
Spokane 5811696, Washington 5815135 99204
Tacoma 5812944, Washington 5815135 98405
Tacoma 5812944, Washington 5815135 98431
Yakima 5816605, Washington 5815135 98902
Burlington 5247214, Wisconsin 5279468 53105
Cudahy 5249871, Wisconsin 5279468 53110
Germantown 5254218, Wisconsin 5279468 53022
Grafton 5254739, Wisconsin 5279468 53024
Green Bay 5254962, Wisconsin 5279468 54311
Kenosha 5258393, Wisconsin 5279468 53142
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Marinette 5261852, Wisconsin 5279468 54143
Marshfield 5261969, Wisconsin 5279468 54449
Milwaukee 5263045, Wisconsin 5279468 53209
Milwaukee 5263045, Wisconsin 5279468 53215
Milwaukee 5263045, Wisconsin 5279468 53226
Milwaukee 5263045, Wisconsin 5279468 53233
Oshkosh 5265838, Wisconsin 5279468 54904
Racine 5268249, Wisconsin 5279468 53406
Sheboygan 5272893, Wisconsin 5279468 53081
Summit, Wisconsin 5279468 53066
Two Rivers 5276609, Wisconsin 5279468 54241
Wauwatosa 5278159, Wisconsin 5279468 53226
West Allis 5278420, Wisconsin 5279468 53227
More Details
- NCT ID
- NCT05602194
- Status
- Recruiting
- Sponsor
- Children's Oncology Group
Detailed Description
PRIMARY OBJECTIVE: I. To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (> 3 mg/dL) during ALL induction therapy for adolescents and young adults (adolescents and young adults [AYAs], age 15-39 years). SECONDARY OBJECTIVES: I. To examine the impact of levocarnitine prophylaxis on differences in the incidence of grade >= 3 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations during ALL Induction. II. To compare rates of minimal residual disease (MRD) positivity at end of Induction and describe MRD+ by end of consolidation (EOC) in those receiving ALL induction chemotherapy with and without levocarnitine. EXPLORATORY OBJECTIVES: I. To compare rates of toxicity and associated dose reductions for chemotherapy administered with and without concomitant levocarnitine supplementation. II. To compare across study arms the peak levels during Induction of conjugated and total bilirubin, AST, ALT, and duration of conjugated hyperbilirubinemia from onset > 3 mg/dL to =< 3 mg/dL. III. To describe the efficacy of levocarnitine prophylaxis to reduce the incidence and/or severity of early patient-reported chemotherapy-induced peripheral neuropathy. IV. To describe the three-year event-free and overall survival (EFS/OS) in those treated with and without levocarnitine prophylaxis. V. To examine the association of age with asparaginase activity and asparaginase-associated hepatotoxicity during induction. VI. To examine the association of body-mass-index (BMI) percentile (or absolute BMI for young adults) with asparaginase activity and asparaginase-associated hepatotoxicity during induction. VII. To describe adherence by self-report and pill-count to oral levocarnitine in patients randomized to the intervention arm. VIII. To examine the association of plasma levels of carnitine and related markers with the efficacy of levocarnitine supplementation. IX. To determine the impact of inherited genetic variation on hepatoxicity and levocarnitine efficacy. OUTLINE: Patients are randomized to 1 of 2 arms (arm A vs. B). ARM A: Patients receive levocarnitine orally (PO) or intravenously (IV) as a bolus over 2 to 3 minutes or by infusion (over 10 to 30 minutes or per institutional standard) starting prior to standard of care induction chemotherapy with pegaspargase or calaspargase pegol and continued through the earlier of the last day of Induction phase (i.e., day prior to start of next phase) or Induction day 35. Patients may also undergo blood sample collection during screening and on study. ARM B: Patients receive standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study. ARM C (RESCUE): Patients in Arms A and B who develop conjugated hyperbilirubinemia > 3 mg/dL during induction may receive levocarnitine rescue PO or IV as a bolus dose over 2 to 3 minutes or by infusion (over 10 to 30 minutes or per institutional standard) until resolution of conjugated hyperbilirubinemia =< 3 mg/dL (or start of consolidation or the next treatment phase, whichever occurs first).